Evidence mapPaperPMID 33922654Full record

ReviewNutrients2021

Creatine Supplementation for Patients with Inflammatory Bowel Diseases: A Scientific Rationale for a Clinical Trial

Theo Wallimann, Caroline H T Hall, Sean P Colgan, Louise E Glover

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02463305 (Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02463305 early_phase1withdrawnnot on this mapstarted 2022, after this paper: background citation

Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD)

TypeinterventionalSponsorUniversity of Colorado, DenverRan2022 to 2023Enrolled0ConditionsColitis, UlcerativeArmsCreatine monohydrate, Placebo
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Evaluation of Creatine Monohydrate Supplementation on the Gastrocnemius Muscle of Mice with Muscular Dystrophy: A Preliminary Study.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

Theo WallimannDepartment of Biology, ETH-Zurich, Emeritus, 8962 Bergdietikon, Switzerland.ORCID 0000-0003-4957-5836
Caroline H T HallMucosal Inflammation Program and Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital Colorado, University of Colorado, 12700 E. 19th Ave, Aurora, CO 80045, USA.
Sean P ColganMucosal Inflammation Program and Department of Medicine, Division of Gastroenterology and Hepatology, University of Colorado, 12700 E 19th Ave, Aurora, CO 80045, USA.
Louise E GloverComparative Immunology Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, D2 Dublin, Ireland.
Children's Hospital Colorado · USETH Zurich · CHTrinity College Dublin · IE

Funding

NCATS NIH HHS KL2 TR002534
6 · The paper itself

Abstract

Based on theoretical considerations, experimental data with cells in vitro, animal studies in vivo, as well as a single case pilot study with one colitis patient, a consolidated hypothesis can be put forward, stating that "oral supplementation with creatine monohydrate (Cr), a pleiotropic cellular energy precursor, is likely to be effective in inducing a favorable response and/or remission in patients with inflammatory bowel diseases (IBD), like ulcerative colitis and/or Crohn's disease". A current pilot clinical trial that incorporates the use of oral Cr at a dose of 2 × 7 g per day, over an initial period of 2 months in conjunction with ongoing therapies (NCT02463305) will be informative for the proposed larger, more long-term Cr supplementation study of 2 × 3-5 g of Cr per day for a time of 3-6 months. This strategy should be insightful to the potential for Cr in reducing or alleviating the symptoms of IBD. Supplementation with chemically pure Cr, a natural nutritional supplement, is well tolerated not only by healthy subjects, but also by patients with diverse neuromuscular diseases. If the outcome of such a clinical pilot study with Cr as monotherapy or in conjunction with metformin were positive, oral Cr supplementation could then be used in the future as potentially useful adjuvant therapeutic intervention for patients with IBD, preferably together with standard medication used for treating patients with chronic ulcerative colitis and/or Crohn's disease.

Indexed as

Clinical Trials as TopicDietary SupplementsCreatineEndpoint DeterminationHumansInflammatory Bowel DiseasesIntestinesCreatineactivated protein kinase (AMPK)Adenosine mono-phosphate (AMP)creatine kinase (CK)creatine perfusioncreatine transporter (CrT)Crohn’s diseaseglucose transporter (GLUT)inflammatory bowel diseases (IBD)intestinal epithelial cell protectionintestinal tissue protectionliver kinase B1 (LKB1)mitochondrial permeability transition pore (mPTP)organ transplantationphosphocreatine (PCr)pleiotropic effects of creatine (Cr) supplementationreactive oxygen species (ROS)ulcerative colitis

Identifiers

PMID33922654
PMCPMC8145094
OpenAlexW3157379745

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.